CL2018002023A1 - Uso de moduladores de receptores de gabaa para el tratamiento de picor. - Google Patents

Uso de moduladores de receptores de gabaa para el tratamiento de picor.

Info

Publication number
CL2018002023A1
CL2018002023A1 CL2018002023A CL2018002023A CL2018002023A1 CL 2018002023 A1 CL2018002023 A1 CL 2018002023A1 CL 2018002023 A CL2018002023 A CL 2018002023A CL 2018002023 A CL2018002023 A CL 2018002023A CL 2018002023 A1 CL2018002023 A1 CL 2018002023A1
Authority
CL
Chile
Prior art keywords
treatment
itching
receptor modulators
gabaa receptor
general formula
Prior art date
Application number
CL2018002023A
Other languages
English (en)
Inventor
Hanns Ulrich Zeilhofer
William Ralvenius
Original Assignee
Univ Zuerich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Zuerich filed Critical Univ Zuerich
Publication of CL2018002023A1 publication Critical patent/CL2018002023A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics

Abstract

SE PROPORCIONA UN COMPUESTO PARA SU USO EN EL TRATAMIENTO DE PICOR, EN EL QUE EL COMPUESTO COMPRENDE LA FÓRMULA GENERAL (1A), FÓRMULA GENERAL (1B) O FÓRMULA GENERAL (1C). LOS COMPUESTOS DE LA INVENCIÓN SON MODULADORES DE RECEPTORES DE GABAA a2 Y/O a3 ALOSTÉRICOS POSITIVOS.
CL2018002023A 2016-01-27 2018-07-26 Uso de moduladores de receptores de gabaa para el tratamiento de picor. CL2018002023A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16153035 2016-01-27
EP16178824 2016-07-11

Publications (1)

Publication Number Publication Date
CL2018002023A1 true CL2018002023A1 (es) 2019-02-01

Family

ID=57890845

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018002023A CL2018002023A1 (es) 2016-01-27 2018-07-26 Uso de moduladores de receptores de gabaa para el tratamiento de picor.

Country Status (14)

Country Link
US (2) US10786513B2 (es)
EP (1) EP3407886A1 (es)
JP (2) JP7115746B2 (es)
KR (1) KR102482200B1 (es)
CN (1) CN108697694B (es)
AU (1) AU2017213154B2 (es)
BR (1) BR112018015386A2 (es)
CA (2) CA3222584A1 (es)
CL (1) CL2018002023A1 (es)
IL (1) IL260775B (es)
MX (1) MX2018009252A (es)
SG (1) SG11201806393QA (es)
UA (1) UA125463C2 (es)
WO (1) WO2017129801A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2018009252A (es) 2016-01-27 2019-01-21 Univ Zuerich Uso de moduladores de receptores de gabaa para el tratamiento de picor.
JP7449272B2 (ja) * 2018-04-18 2024-03-13 ニューロサイクル・セラピューティクス・インコーポレイテッド Ｇａｂａａ陽性アロステリックモジュレーター化合物、その作製の方法および使用
EP3796907A4 (en) * 2018-05-22 2021-11-03 Neurocycle Therapeutics, Inc. GABAA POSITIVE ALLOSTERIC MODULATING COMPOUNDS FOR THE TREATMENT OF PRURITUS AND / OR DERMATITIS
EP3849976B1 (en) 2018-09-13 2022-10-26 Saniona A/S A gaba a receptor ligand
WO2020191047A1 (en) * 2019-03-18 2020-09-24 Neurocycle Therapeutics, Inc. Use of gabaa receptor modulators for treatment of pain
CN110004118B (zh) * 2019-03-29 2023-03-28 中国科学院武汉物理与数学研究所 用于辅助重组狂犬病毒在神经细胞高效逆向跨单级突触的rAAV病毒的包装方法及其应用
JP2022554159A (ja) * 2019-10-23 2022-12-28 ニューロサイクル・セラピューティクス・インコーポレイテッド Ｇａｂａａ受容体モジュレーターによるてんかん状態の治療
US20210401849A1 (en) * 2020-06-30 2021-12-30 University Of Mississippi Medical Center Methods for treating benzodiazepine misuse/use disorder

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1024526A (en) 1911-07-25 1912-04-30 George R Schweikert Chair.
SK9399A3 (en) * 1996-07-25 2000-04-10 Merck Sharp & Dohme Substituted triazolo-pyridazine derivatives as ligands for gaba receptors
FR2767692B1 (fr) * 1997-09-01 2000-03-03 Oreal Utilisation d'une substance agoniste d'un recepteur associe a un canal chlore ou potassique dans le traitement des peaux sensibles
GB9813576D0 (en) 1998-06-24 1998-08-19 Merck Sharp & Dohme Therapeutic agents
GB9903119D0 (en) * 1999-02-11 1999-04-07 Merck Sharp & Dohme Therapeutic agents
US6936608B2 (en) 2000-11-10 2005-08-30 Merck Sharp & Dohme Ltd. Imidazo-triazine derivatives as ligands for GABA receptors
GB0117277D0 (en) 2001-07-16 2001-09-05 Merck Sharp & Dohme Therapeutic agents
TWI248936B (en) 2001-03-21 2006-02-11 Merck Sharp & Dohme Imidazo-pyrimidine derivatives as ligands for GABA receptors
US8835424B2 (en) 2002-03-28 2014-09-16 Wisconsin Alumni Research Foundation Selective agents for pain suppression
KR100865410B1 (ko) 2002-03-28 2008-10-24 위시스 테크놀로지 파운데이션, 인크. 진정 및 운동실조 효과가 감소된 항불안제
GB0210124D0 (en) 2002-05-02 2002-06-12 Merck Sharp & Dohme Therapeutic agents
JP2004170323A (ja) * 2002-11-22 2004-06-17 Sumitomo Pharmaceut Co Ltd 皮膚疾患治療剤のスクリーニング方法
JPWO2005030773A1 (ja) * 2003-09-26 2006-12-07 大日本住友製薬株式会社 新規ピラゾロピリミジン誘導体
WO2005108401A1 (en) * 2004-04-29 2005-11-17 Dov Pharmaceutical, Inc. 2-pyridinyl[7-(substituted-pyridin-4-yl) pyrazolo[1,5-a]pyrimidin-3-yl]methanones
WO2006061428A2 (en) * 2004-12-10 2006-06-15 Universität Zürich Gaba-a alpha 2 and alpha 3 receptor agonists for treating neuropathic, inflammatory and migraine associated pain
KR20060087386A (ko) * 2005-01-28 2006-08-02 주식회사 대웅제약 신규 벤조이미다졸 유도체 및 이를 함유하는 약제학적조성물
ATE494289T1 (de) 2006-08-04 2011-01-15 Merz Pharma Gmbh & Co Kgaa Substituierte pyrazolopyrimidine, ein verfahren zu ihrer herstellung und ihre verwendung als medizin
ES2689444T3 (es) 2006-11-22 2018-11-14 Incyte Holdings Corporation Imidazotriazinas e imidazopirimidinas como inhibidores de la quinasa
EP2188284A2 (en) * 2007-08-14 2010-05-26 Novartis Ag Tricyclic heterocyclic compounds as gaba a modulators
SI2300455T1 (sl) 2008-05-21 2017-12-29 Incyte Holdings Corporation Soli 2-fluoro-n-metil-4-(7-(kinolin-6-il-metil)-imidazo(1,2-b)1,2,4) triazin-2-il)benzamid in postopki v zvezi z njihovo pripravo
WO2010063487A1 (en) 2008-12-05 2010-06-10 Merz Pharma Gmbh & Co. Kgaa Pyrazolopyrimidines, a process for their preparation and their use as medicine
EP2421848A1 (en) 2009-04-22 2012-02-29 Janssen Pharmaceutica N.V. Azetidinyl diamides as monoacylglycerol lipase inhibitors
WO2011011712A1 (en) 2009-07-24 2011-01-27 Concert Pharmaceuticals, Inc. Substituted imidazotriazines
ES2573148T3 (es) 2010-08-25 2016-06-06 Neopharm Co., Ltd. Compuestos y composición de 1H-benzo[d]imidazol-5-ilo para el tratamiento de enfermedades inflamatorias
US20130331394A1 (en) * 2012-06-11 2013-12-12 The Mclean Hospital Corporation Treating schizophrenia
BR122017003181A2 (pt) * 2013-02-19 2019-09-10 Ono Pharmaceutical Co composto inibidor de trk, composição farmacêutica e medicamento compreendendo dito composto e seu uso para profilaxia e/ou terapia de doença relacionada à trk e/ou para inibir trk
WO2015072853A1 (en) 2013-11-13 2015-05-21 Rjg Developments B.V. Treatment of herpes virus infection outbreaks
GB201321732D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
US9844551B2 (en) 2015-01-14 2017-12-19 Children's Hospital Medical Center Compositions and methods for treatment of fragile X syndrome
US10259815B2 (en) 2015-03-20 2019-04-16 Uwm Research Foundation, Inc. Gabaergic ligands and their uses
MX2018009252A (es) 2016-01-27 2019-01-21 Univ Zuerich Uso de moduladores de receptores de gabaa para el tratamiento de picor.

Also Published As

Publication number Publication date
CA3222584A1 (en) 2017-08-03
JP2019507736A (ja) 2019-03-22
US20190134057A1 (en) 2019-05-09
IL260775B (en) 2021-09-30
CA3012791A1 (en) 2017-08-03
EP3407886A1 (en) 2018-12-05
US11529359B2 (en) 2022-12-20
JP7115746B2 (ja) 2022-08-09
UA125463C2 (uk) 2022-03-16
CN108697694B (zh) 2022-12-09
WO2017129801A1 (en) 2017-08-03
US20210100814A1 (en) 2021-04-08
KR102482200B1 (ko) 2022-12-27
US10786513B2 (en) 2020-09-29
CA3012791C (en) 2024-01-23
BR112018015386A2 (pt) 2019-03-19
SG11201806393QA (en) 2018-08-30
AU2017213154B2 (en) 2023-02-02
AU2017213154A1 (en) 2018-08-16
CN108697694A (zh) 2018-10-23
KR20180118623A (ko) 2018-10-31
JP2022088620A (ja) 2022-06-14
RU2018128905A (ru) 2020-02-27
RU2018128905A3 (es) 2020-03-24
MX2018009252A (es) 2019-01-21

Similar Documents

Publication Publication Date Title
CL2018002023A1 (es) Uso de moduladores de receptores de gabaa para el tratamiento de picor.
CR20190071A (es) Compuestos, composiciones y métodos para el tratamiento de enfermedades
CL2018000595A1 (es) Anticuerpos anti-pd1 y métodos de uso
ECSP18044917A (es) Compuestos inhibidores de la quinasa de unión a tank
CO2018008761A2 (es) Derivados de maitansinoide, conjugados de los mismos métodos de uso
SV2018005794A (es) Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos
CR20160500A (es) Anticuerpos anti-ox40 y métodos de uso
CR20160419A (es) Nuevos compuestos biciclicos
DOP2017000289A (es) Moduladores de receptor nuclear
CL2016001911A1 (es) Compuesto heterocíclico fusionado
DOP2015000270A (es) Potenciador de inhibidores del homólogo de zeste
CL2019000189A1 (es) Nuevos anticuerpos anti-claudina y sus métodos de uso. (divisional solicitud 201801481)
CL2018003087A1 (es) Síntesis de indazoles.
GT201700023A (es) Derivados de heterociclico opcionalmente condensados de piridimina útiles para el tratamiento de enfermedades inflamatorias, metabolicas, oncológicas y autoinmunitarias
CL2015001377A1 (es) Inhbibidores de bmi-1 primidinas sustituidas inversas
CL2018003085A1 (es) Síntesis de indazoles
CO2019005552A2 (es) Compuestos de bencenosulfonamida y su uso como agentes terapéuticos
CL2018002533A1 (es) Procedimientos para el tratamiento de la depresíón usando antagonisdas de los receptores de orexina-2.
CL2017000505A1 (es) Proceso para la elaboración de derivados de pirimidin sulfamida.(div. sol. 2008-2016).
GT201700231A (es) Azabenzimidazoles y su uso como moduladores del receptor ampa
CL2020000101A1 (es) Compuestos de cetonas bicíclicas y métodos de uso de los mismos.
CO2020015747A2 (es) Analogos de rapamicina y usos de los mismos
CL2018001252A1 (es) Métodos para tratar esclerosis múltiple usando compuestos de pirimidina y piridina con actividad inhibidora de tirosina cinasa de bruton
CL2018003121A1 (es) Inhibidores del potenciador del homólogo zeste 2.
CL2019001991A1 (es) Moduladores del receptor de estrógeno.